J. Martijn Kerst

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +13

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Nathan I. Cherny, Richard Sullivan, Urania Dafni et al. · Annals of Oncology · 2015 · 807 citations · Full text

Medicine, Oncology, Medical Oncology +15

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

Maria De Santis, Joaquim Bellmunt, Graham M. Mead et al. · Journal of Clinical Oncology · 2011 · 773 citations · Full text

Medicine, Oncology, Pharmacology +13

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst et al. · The Lancet Oncology · 2014 · 387 citations

Medicine, Oncology, Urology +11

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

Piotr Rutkowski, Alessandro Gronchi, Peter Hohenberger et al. · Annals of Surgical Oncology · 2013 · 242 citations

Medicine, Oncology, Gastrointestinal Oncology +11